GLAUKOS Corp (GKOS) Stock Analysis and Metrics

Glaukos

NYSE: GKOS

$153.65 ▲ +1.52 (+1.00%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap8.83 Bn

P/E-45.36

P/S16.02

Div. Yield0.00

Revenue Growth (1y) (Qtr)41.16

Add ratio to table…

About

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease. The company pioneered Micro Invasive Glaucoma Surgery (MIGS) with its iStent family of devices and has expanded into sustained release pharmaceuticals such as iDose TR, bio activated corneal crosslinking therapies under the iLink platform, transdermal formulations via the iLution platform, and posterior segment drug delivery implants under the Retinal XR platform. Glaukos Corp operates primarily in the United States with expanding international presence in Europe, Asia, and Latin America.

Glaukos Corp generates revenue principally from the sale of its medical devices and pharmaceutical products to eye care providers. The company's iStent family of micro scale surgical devices, the iDose TR intracameral pharmaceutical implant, and related glaucoma accessories together accounted for approximately 79% of net sales in 2024, while its iLink therapies for corneal crosslinking contributed roughly 21% of net sales in the same year. Sales are made directly to ambulatory surgery centers, hospitals, and physician private practices, with approximately 70% of 2024 net sales originating from the United States and the remaining 30% from international markets. No single customer or distributor represented more than 10% of total net sales in 2024.

The company operates through the following segment:

• Ophthalmic therapies: This segment encompasses the development and commercialization of therapies for glaucoma, corneal disorders, and retinal disease, including MIGS devices, sustained release pharmaceutical implants, bio activated corneal crosslinking systems, transdermal formulations, and posterior segment drug delivery platforms.

Glaukos Corp holds a distinctive position in the ophthalmic medical technology and pharmaceutical sectors. In the glaucoma market, its MIGS offerings compete with products from Alcon (following its acquisition of Ivantis), Sight Sciences, and New World Medical, while its procedural pharmaceutical iDose TR faces competition principally from AbbVie. For corneal disorders, the company is the sole holder of an FDA approved bio activated pharmaceutical therapy for keratoconus, although it contends with various providers of corneal crosslinking procedures such as PeschkeTrade GmBH. Should its anterior segment pipeline receive regulatory approval, Glaukos Corp would encounter broader competition from large entities including AbbVie, Alcon, and Johnson & Johnson, and its posterior segment pipeline could be challenged by Novartis, Genentech/Roche, Regeneron Pharmaceuticals, and Bayer AG. The company emphasizes competitive advantages rooted in clinical superiority supported by extensive data, innovative features that improve patient benefit, product performance, and safety.

Glaukos Corp serves ophthalmic surgeons and other eye care professionals through a customer base that principally includes ambulatory surgery centers, hospitals, and physician private practices. The company does not disclose the names of individual customers, but it notes that no single customer or distributor accounted for more than ten percent of its total net sales in 2024, indicating a diversified client base across both domestic and international markets.

Investment Thesis

▲ Bull case

Glaukos is positioned to capitalize on a significant inflection point in its growth trajectory driven by the dual engines of iDose TR and Epioxa, with iDose TR already generating $54 million in Q1 2026 sales and demonstrating strong clinical adoption supported by 22 peer-reviewed publications and expanding real-world evidence from Phase IV studies, which reinforces its role in shifting glaucoma care toward earlier intervention and creates a durable competitive moat that is underappreciated by the market focused solely on near-term reimbursement headwinds in certain MAC jurisdictions.
The Epioxa launch represents a transformative opportunity beyond simply replacing Photrexa, as management highlighted a true addressable market of 50,000 to 100,000 keratoconic eyes annually requiring treatment—far exceeding the historical 18,000–19,000 treated under Photrexa—supported by strategic investments in a Sidecar network covering 65% of the U.S. population with a clear path to 95%, payer policy updates with four of the five largest commercial payers, and the imminent CMS J-code J2789 effective July 1, 2026, which will streamline reimbursement and unlock broader adoption that the market is underestimating due to early-stage launch noise.
Glaukos’ pipeline diversification is a hidden catalyst, with ongoing Phase II trials for iLution Demodex blepharitis (GLK-321) targeting a large, underpenetrated market, advancement of the Link platform including a KC screening device launch later in 2026, and progress on iDose TREX and iStent Infinite trials, which collectively de-risk reliance on current franchises and position the company to sustain double-digit growth well into the next decade through ROI-driven innovation in dropless technologies, a narrative not fully reflected in current valuations focused on near-term EPS volatility.
Operating leverage is emerging faster than anticipated, evidenced by Q1 2026 non-GAAP gross margin expansion to 84% (up 200 bps YoY) and a reduction in non-GAAP operating loss to $10.5 million from $15.2 million YoY, driven by scalable commercial execution in iDose TR and disciplined reinvestment in high-ROI initiatives like DTC and patient access programs, signaling a clearer path to cash flow breakeven and profitability than the market expects given the current focus on SG&A growth without recognizing the operating leverage embedded in the franchise expansion.
International glaucoma franchise resilience is underappreciated, with Q1 2026 international sales growing 23% reported (16% constant currency) to $35.8 million, supported by iStent Infinite’s EU MDR certification and European launch, which offsets competitive headwinds in certain markets and demonstrates the company’s ability to adapt its commercial strategy globally, a factor the market overlooks when fixating on U.S.-centric reimbursement risks.

Glaukos is positioned to capitalize on a significant inflection point in its growth trajectory driven by the dual engines of iDose TR and Epioxa, with iDose TR already generating $54 million in Q1 2026 sales and demonstrating strong clinical adoption supported by 22 peer-reviewed publications and expanding real-world evidence from Phase IV studies, which reinforces its role in shifting glaucoma care toward earlier intervention and creates a durable competitive moat that is underappreciated by the market focused solely on near-term reimbursement headwinds in certain MAC jurisdictions.
The Epioxa launch represents a transformative opportunity beyond simply replacing Photrexa, as management highlighted a true addressable market of 50,000 to 100,000 keratoconic eyes annually requiring treatment—far exceeding the historical 18,000–19,000 treated under Photrexa—supported by strategic investments in a Sidecar network covering 65% of the U.S. population with a clear path to 95%, payer policy updates with four of the five largest commercial payers, and the imminent CMS J-code J2789 effective July 1, 2026, which will streamline reimbursement and unlock broader adoption that the market is underestimating due to early-stage launch noise.
Glaukos’ pipeline diversification is a hidden catalyst, with ongoing Phase II trials for iLution Demodex blepharitis (GLK-321) targeting a large, underpenetrated market, advancement of the Link platform including a KC screening device launch later in 2026, and progress on iDose TREX and iStent Infinite trials, which collectively de-risk reliance on current franchises and position the company to sustain double-digit growth well into the next decade through ROI-driven innovation in dropless technologies, a narrative not fully reflected in current valuations focused on near-term EPS volatility.
Operating leverage is emerging faster than anticipated, evidenced by Q1 2026 non-GAAP gross margin expansion to 84% (up 200 bps YoY) and a reduction in non-GAAP operating loss to $10.5 million from $15.2 million YoY, driven by scalable commercial execution in iDose TR and disciplined reinvestment in high-ROI initiatives like DTC and patient access programs, signaling a clearer path to cash flow breakeven and profitability than the market expects given the current focus on SG&A growth without recognizing the operating leverage embedded in the franchise expansion.
International glaucoma franchise resilience is underappreciated, with Q1 2026 international sales growing 23% reported (16% constant currency) to $35.8 million, supported by iStent Infinite’s EU MDR certification and European launch, which offsets competitive headwinds in certain markets and demonstrates the company’s ability to adapt its commercial strategy globally, a factor the market overlooks when fixating on U.S.-centric reimbursement risks.

▼ Bear case

Glaukos faces significant near-term headwinds in U.S. glaucoma reimbursement sustainability, as evidenced by the shifting adoption dynamics where Noridian and Novitas First Coast—historically high-adopting MAX jurisdictions—declined to just 7% of region volumes in Q1 2026 from 78% in Q4 2025, signaling potential fragility in reimbursement stability despite management’s optimism about NGS and Palmetto adoption, and the absence of LCDs in key MACs remains an unaddressed risk that could impede iDose TR’s long-term margin expansion if broader commercial and Medicare Advantage uptake does not materialize as expected.
The Epioxa launch is encountering meaningful commercialization friction that management is downplaying, including elongated patient access pathways due to the miscellaneous J-code environment requiring claim-by-claim adjudication, specialty pharmacy channel friction as physicians adapt to new workflows after years of buy-and-bill with Photrexa, and payer policy adoption progressing slower than anticipated despite early receptivity from four of the top five payers, all of which could delay the ramp to meaningful volume and keep Epioxa revenue subscale through 2026, contradicting the bullish narrative of rapid market expansion.
Gross margin expansion is misleading and not sustainable, as GAAP gross margin remained flat at approximately 78% in Q1 2026 versus 77% in Q1 2025, with the reported 84% non-GAAP margin relying on adjustments that exclude acquisition-related costs, intangible amortization, and other non-core items, raising concerns about true underlying profitability as the company scales Epioxa and iDose TR, particularly given rising SG&A expenses (up 32% to $92.9 million) and R&D spend (up 36% to $44.1 million) that are not being offset by proportional gross profit growth.
The company’s guidance uplift to $620–$635 million for FY 2026 relies heavily on continued iDose TR strength and assumes flat non-iDose U.S. glaucoma sales, yet management admitted they are not ready to call the stabilization of the core glaucoma franchise a “new normal,” implying that the apparent resilience in non-iDose sales could be temporary and driven by transitory factors like supply chain disruptions affecting competitors, which, if reversed, would undermine the foundation of the raised guidance and expose overreliance on iDose TR alone.
International growth is increasingly vulnerable to structural headwinds, as management acknowledged expectations of new competitive product trials in major international markets and noted that currency tailwinds are abating, with constant currency growth (16%) significantly lagging reported growth (23%) in the glaucoma franchise, suggesting that the reported strength is partly FX-driven and not reflective of organic demand, a risk amplified by the lack of discussion on pricing pressure or market share erosion in key ex-U.S. regions.

Glaukos faces significant near-term headwinds in U.S. glaucoma reimbursement sustainability, as evidenced by the shifting adoption dynamics where Noridian and Novitas First Coast—historically high-adopting MAX jurisdictions—declined to just 7% of region volumes in Q1 2026 from 78% in Q4 2025, signaling potential fragility in reimbursement stability despite management’s optimism about NGS and Palmetto adoption, and the absence of LCDs in key MACs remains an unaddressed risk that could impede iDose TR’s long-term margin expansion if broader commercial and Medicare Advantage uptake does not materialize as expected.
The Epioxa launch is encountering meaningful commercialization friction that management is downplaying, including elongated patient access pathways due to the miscellaneous J-code environment requiring claim-by-claim adjudication, specialty pharmacy channel friction as physicians adapt to new workflows after years of buy-and-bill with Photrexa, and payer policy adoption progressing slower than anticipated despite early receptivity from four of the top five payers, all of which could delay the ramp to meaningful volume and keep Epioxa revenue subscale through 2026, contradicting the bullish narrative of rapid market expansion.
Gross margin expansion is misleading and not sustainable, as GAAP gross margin remained flat at approximately 78% in Q1 2026 versus 77% in Q1 2025, with the reported 84% non-GAAP margin relying on adjustments that exclude acquisition-related costs, intangible amortization, and other non-core items, raising concerns about true underlying profitability as the company scales Epioxa and iDose TR, particularly given rising SG&A expenses (up 32% to $92.9 million) and R&D spend (up 36% to $44.1 million) that are not being offset by proportional gross profit growth.
The company’s guidance uplift to $620–$635 million for FY 2026 relies heavily on continued iDose TR strength and assumes flat non-iDose U.S. glaucoma sales, yet management admitted they are not ready to call the stabilization of the core glaucoma franchise a “new normal,” implying that the apparent resilience in non-iDose sales could be temporary and driven by transitory factors like supply chain disruptions affecting competitors, which, if reversed, would undermine the foundation of the raised guidance and expose overreliance on iDose TR alone.
International growth is increasingly vulnerable to structural headwinds, as management acknowledged expectations of new competitive product trials in major international markets and noted that currency tailwinds are abating, with constant currency growth (16%) significantly lagging reported growth (23%) in the glaucoma franchise, suggesting that the reported strength is partly FX-driven and not reflective of organic demand, a risk amplified by the lack of discussion on pricing pressure or market share erosion in key ex-U.S. regions.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password